Latest Saniona News & Updates
See the latest news and media coverage for Saniona. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing ion channel modulators
saniona.com- Headquarters
- Glostrup, Denmark
- Founded year
- 2011
- Company type
- Private company
- Number of employees
- 40–50
Last updated
Latest news about Saniona
In short: Saniona transitioned into a clinical execution phase following a licensing agreement with Jazz Pharmaceuticals and the selection of SAN2668.
Company announcements
-
Saniona selects SAN2668 as clinical candidate for paediatric epilepsy
SAN2668 addresses sedation, cognitive impairment, and tolerance. The company advances three programs to Phase 2 and initiates preclinical development for Phase 1 in 2026.
-
Saniona hosts Q2 investor call
The call occurs on 28 August at 13:00 CET. Management presents results, updates, and hosts a Q&A session.
-
Saniona enters exclusive licensing agreement with Jazz Pharmaceuticals
Saniona receives $42.5 million upfront plus potential milestones and royalties for SAN2355.
-
Saniona publishes the annual report for 2025
The annual report is available on the company's website. The information is disclosed in accordance with the Securities Market Act.
Media coverage
-
Saniona enters clinical execution phase after a transformative year - Biostock
Saniona’s performance in 2025 was driven by the strategically important agreements secured with Jazz Pharmaceuticals in 2025 and Acadia Pharmaceuticals in 2024. Together, these have...
-
Saniona AB (FRA:30S) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial ...
Saniona AB (FRA:30S) strengthened its financial position in 2025, ending the year with approximately 581 million crowns in cash. The company secured significant pharmaceutical partnerships...
-
Saniona reports operating loss | MarketScreener Spain
The research company Saniona reports a decrease in its revenue during the fourth quarter compared to the same period of the previous year. The...
-
Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug
Epilepsy is already represented in Jazz Pharmaceuticals' portfolio by Epidiolex, a drug that treats seizures caused by three rare types of this brain disorder. Epilepsies...
Track Saniona and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Saniona competitors & trending companies
Browse news for competitors to Saniona and other trending companies.
Herantis Pharma
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove